CompletedPhase 3

Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis

Italy, Spain312 participantsStarted 2013-03

Plain-language summary

Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite. Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis.

Who can participate

Age range6 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female patients older than 5 years and weighting \> 15 kg * Current residence in non-endemic areas * Either direct diagnosis of S. stercoralis infection AND positive serology at any titer OR positive serology at "high" titer, irrespective of results of direct tests Exclusion Criteria: * Pregnant or lactating women * Subjects suffering from CNS diseases * Disseminated strongyloidiasis * Immunocompromised patients. * Lack of informed consent * Previous treatment with ivermectin (in the last year)

What they're measuring

clearance of strongyloides infection

Timeframe: 12 months

Trial details

NCT IDNCT01570504

SponsorCentro per le Malattie Tropicali

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-06-08

View on ClinicalTrials.gov More Strongyloidiasis trials